Success by numbers
87
pieces of coverage in six months, including 60 Tier One placements
43%
increase in share of voice
11
key political and patient stakeholders engaged and educated
Shaping the UK obesity debate with Juniper: from 6% to 49% share of voice
Integrated PR and policy communications to reshape the obesity debate, protect reputation, and build commercial momentum in the UK health tech sector.
The partnership
Juniper is a digital weight management service that combines clinically proven GLP‑1 medication with ongoing health coaching, tracking, clinical consultations, and a dedicated support team to provide NICE‑endorsed obesity care.
Entering the UK market, Juniper needed to navigate intense media scrutiny of weight loss drugs, sceptical policymakers, and a complex NHS landscape, while demand for effective obesity treatment continued to rise. Public debate often framed medication as a quick fix, with political focus concentrated on prevention and the food system alone. At the same time, strict NHS eligibility criteria and fragmented referral pathways limited access for those who could benefit most.
Juniper’s leadership asked Clarity to position the brand as a responsible provider of wraparound care, build credibility with journalists and political stakeholders, increase share of voice in a crowded conversation, and create the foundations for sustainable growth in a highly scrutinised category.
Systematising impact
Clarity aligned Juniper’s media, policy, and digital activity into a single strategy designed to shift the obesity narrative from quick fixes to clinically governed, holistic care. Using Clarity’s Now, Near, Next framework, the team built a clear point of view on obesity pathways, grounded it in patient experience, and translated it into tailored narratives for journalists, parliamentarians, and patient groups.
Clarity prioritised senior stakeholder engagement, cultivating high‑trust relationships in Westminster and across the health ecosystem, then convened those voices in Parliament to generate credible, shared recommendations. A Westminster‑launched report, supported by integrated content, design, and digital promotion, provided a structural platform for ongoing dialogue on national obesity policy and access to GLP‑1 medication.
This systematised approach enabled Juniper to demonstrate leadership on obesity, manage regulatory risk, and convert scrutiny into informed engagement and commercial momentum.
